Elekta Valuation Multiples

Elekta Overview

About Elekta

Sweden-based Elekta develops, manufactures, and distributes treatment planning systems for neurosurgery and radiotherapy, including stereotactic radiosurgery and brachytherapy. The company has an installed base of more than 7,300 linear accelerators, Gamma Knife and Unity platforms, as well as brachytherapy installations. The company's sales are evenly distributed across geographies, with North and South America accounting for 30%; Europe, the Middle East, and Africa accounting for 36%; and the Asia-Pacific contributing the remainder.

Founded

1972

HQ

Employees

4.6K

Website

elekta.com

Sectors

Medical DevicesBioTechLongevity

Financials (LTM)

Revenue: $2B

EBITDA: $304M

EV

$3B

Valuation Multiples

Multiples.vc

Start free trial

Elekta Financials

Elekta reported last 12-month revenue of $2B and EBITDA of $304M.

In the same LTM period, Elekta generated $650M in gross profit, $304M in EBITDA, and $94M in net income.

Elekta P&L

In the most recent fiscal year, Elekta reported revenue of $2B and EBITDA of $374M.

Elekta expects next 12-month revenue of XXX and NTM EBITDA of XXX

Elekta Stock Performance

Elekta has current market cap of $2B, and enterprise value of $3B.

Elekta's stock price is $6.34.

Elekta Valuation Multiples

Elekta trades at 1.6x EV/Revenue multiple, and 9.7x EV/EBITDA.

Elekta Financial Valuation Multiples

As of April 20, 2026, Elekta has market cap of $2B and EV of $3B.

Equity research analysts estimate Elekta's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Elekta has a P/E ratio of 25.8x.

Elekta Margins & Growth Rates

Elekta's revenue in the last 12 month grew by 4%.

Elekta's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.

Elekta's rule of 40 is 19% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Elekta's rule of X is 20% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Elekta Public Comps

See public comps and valuation multiples for other Medical Devices comps.

Elekta M&A Activity

Elekta acquired XXX companies to date.

Last acquisition by Elekta was on XXXXXXXX, XXXXX. Elekta acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Elekta Investment Activity

Elekta invested in XXX companies to date.

Elekta made its latest investment on XXXXXXXX, XXXXX. Elekta invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).